Evidence map›Paper›PMID 41616265›Full record

Trial reportAntimicrobial agents and chemotherapy2026

Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study.

Borje Darpo, Jerry Nedelman, Rebecca Bruning-Barry, Dean Hickman, Robert Kleiman, Antonio Lombardi, Hongqi Xue

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Borje DarpoClario, Philadelphia, Pennsylvania, USA.
Jerry NedelmanTB Alliance, New York, New York, USA.ORCID 0000-0002-0205-522X
Rebecca Bruning-BarryRTI International, Durham, North Carolina, USA.ORCID 0000-0003-1229-247X
Dean HickmanTB Alliance, New York, New York, USA.
Robert KleimanClario, Philadelphia, Pennsylvania, USA.
Antonio LombardiTB Alliance, New York, New York, USA.ORCID 0009-0001-7383-2495
Hongqi XueClario, Philadelphia, Pennsylvania, USA.

Funding

Bill and Melinda Gates Foundation OPP1129600Bundesministerium für Bildung und Forschung 5150 00 344Department of Foreign Affairs and Trade, Australian Government 78836Foreign and Commonwealth Office 400499-402Irish Aid TB Alliance 2024United States Agency for International Development 7200AA21CA00021
6 · The paper itself

Abstract

Sorfequiline (TBAJ-876) is a novel diarylquinoline under development for tuberculosis. In a first-in-human, multiple-ascending-dose study, electrocardiogram and pharmacokinetic data were analyzed to assess cardiac repolarization. Placebo-corrected change-from-baseline in QTcF (ΔΔQTcF) ranged from -11.4 to +2.4 ms without dose dependency. Concentration-QTc modeling showed a shallow, non-significant slope. The predicted mean effect on ΔΔQTcF at the maximum geometric mean C

Indexed as

Antitubercular AgentsDiarylquinolinesAdultDouble-Blind MethodElectrocardiographyFemaleHumansMaleAntitubercular AgentsDiarylquinolinesconcentration-QTc (C-QTc)first-in-humanmultidrug resistanceQTctuberculosis

Identifiers

PMID41616265
PMCPMC12959150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.